The human body's capacity to heal itself has always had limits — and in those limits, people die. A team of researchers in Canada and the United States has moved to close one of those gaps, engineering blood clots that form faster and hold stronger than anything biology produces on its own. Using a technique that chemically fortifies the red blood cells themselves, rather than the fragile protein scaffolding around them, they have created a material that may one day give surgeons and trauma teams a few more precious seconds — and those seconds, in medicine, are often everything.
Scientists Create Super-Clots That Form in Seconds, Offering New Hope for Severe Bleeding
Red blood cells could play a central structural role
Mark
Why does it matter that you're using red blood cells as the building material instead of just engineering the fibrin?
Mimi
Because red blood cells make up half the volume of a natural clot, but nobody was really using them. They're weak on their own, so researchers ignored them and focused on the tiny fibrin scaffold. We realized: what if we made the abundant material strong instead of trying to engineer the scarce material harder?
Mark
And the "click clotting" name—what's actually happening chemically?
Mimi
It's a rapid chemical reaction that binds the red blood cells together. The reactions are fast and safe, which is crucial because you can't wait around in an emergency. The whole gel forms in minutes, not hours.
Mark
You tested this in rats. What made you confident enough to say this could work in humans?
Mimi
The clots sealed liver injuries without triggering immune rejection or toxicity. That's the baseline you need to clear. But rats aren't people—their blood chemistry is different, their wound environments are different. We need human trials to know if this actually works when it matters.
Mark
What's the hardest problem you still have to solve?
Mimi
High-pressure bleeding. If an artery ruptures, the pressure is immense. Our gel isn't strong enough yet to hold against that. We need to tune the formula differently for different scenarios—organ repair versus arterial trauma versus surgical oozing. It's not one-size-fits-all.
Mark
For someone on blood thinners, this could be genuinely life-changing?
Mimi
Yes. Blood thinners save you from clots forming where they shouldn't—in your veins or arteries. But they also cripple your ability to form protective clots when you're injured. An engineered clot that's stronger and faster could give you back that protection without stopping the medication.
Mark
What's your timeline for human trials?
Mimi
That's not my call to make. The science is ready. Now it's regulatory pathways, funding, clinical protocols. If everything moves quickly, maybe a few years. But "quickly" in medicine is a relative term.
Le Pouls
- Natural blood clots fail people every day — forming too slowly or fracturing under pressure when the bleeding is severe enough to matter.
- The 'click clotting' breakthrough reengineers the clot from the inside out, turning structurally weak red blood cells into load-bearing material and producing something 13 times harder to fracture than what the body makes.
- A usable patch can be prepared in as little as 10 minutes from donor blood, fast enough to be relevant in trauma bays and operating rooms where time is the enemy.
- Animal trials in rats showed the clots sealed liver injuries without triggering immune rejection — a critical early hurdle cleared on the road to human use.
- The technology is not yet ready for the full range of emergencies it hopes to address — high-pressure arterial bleeds remain beyond its current capability, and human clinical trials have not yet begun.
The human body's capacity to heal itself has always had limits — and in those limits, people die. A team of researchers in Canada and the United States has moved to close one of those gaps, engineering blood clots that form faster and hold stronger than anything biology produces on its own. Using a technique that chemically fortifies the red blood cells themselves, rather than the fragile protein scaffolding around them, they have created a material that may one day give surgeons and trauma teams a few more precious seconds — and those seconds, in medicine, are often everything.
When the body's own clotting response is too slow or too weak, people bleed out. It is a failure mode that medicine has long struggled to overcome. Now, a research team spanning Canada and the United States believes they have found a more powerful answer.
Their method, called 'click clotting,' produces engineered blood clots — EBCs — that form in seconds and outperform natural clots by a wide margin. In laboratory testing, they proved 13 times more resistant to fracturing and four times more adhesive than what the body generates on its own. The key insight was architectural: rather than reinforcing the fibrin fibers that scaffold a natural clot, the McGill University team led by mechanical engineer Jianyu Li focused on the red blood cells themselves. Though they make up roughly half a clot's volume, red blood cells are mechanically fragile. By chemically binding them together through rapid, safe reactions, the researchers transformed them into structural material — producing a gel called a cytogel that can be applied directly to a wound.
Preparation is fast enough to matter in real emergencies. A donor-blood version takes about 10 minutes; one made from the patient's own blood takes around 20. In rat models, the clots sealed liver injuries without triggering immune reactions or toxicity — an encouraging early result. Researchers see particular promise for trauma surgery and for patients on blood thinners whose bodies cannot form reliable clots naturally.
Still, the road ahead is long. Human trials have not yet begun, and the current formulation cannot handle high-pressure arterial bleeds. The team will need to tailor the gel's properties to different clinical scenarios before it can be widely deployed. The promise is genuine — but it remains a laboratory achievement waiting to be tested in the far less predictable world of actual medicine.
When you cut yourself badly enough, your body springs into action. Platelets and proteins rush to the wound, forming a mesh that traps blood cells and stops the bleeding. It's elegant, automatic, and often enough. But sometimes it isn't. Sometimes the clot forms too slowly, or too weakly, and a person bleeds out before their own biology can save them.
Researchers across Canada and the United States have now engineered a faster, stronger version of this life-saving process. They've created what they call engineered blood clots, or EBCs, using a technique they've named "click clotting." The clots form in seconds rather than minutes, and they're dramatically more durable than what the body produces on its own. In laboratory tests, these artificial clots proved 13 times more resistant to fracturing and four times more adhesive than natural ones.
The innovation hinges on a shift in how scientists think about what makes a clot strong. Natural blood clots are roughly half red blood cells by volume, but those cells are mechanically weak—they fracture easily under pressure. Researchers have traditionally tried to strengthen clots by engineering the fibrin fibers, the protein scaffolding that provides structure. But fibrin makes up less than one percent of a natural clot. The McGill University team, led by mechanical engineer Jianyu Li, took a different approach: they made the red blood cells themselves into sturdier building blocks. Using rapid, safe chemical reactions, they bound the cells together, transforming them from fragile components into structural material. The resulting gel, called a cytogel, can be applied directly to a wound as a patch.
The preparation is fast enough for real emergencies. A version made from donor blood—type-matched to avoid rejection—takes about 10 minutes to prepare. A version using the patient's own blood takes roughly 20 minutes. In animal models, the clots successfully sealed injuries to rat livers without triggering dangerous immune reactions or toxicity. The team sees particular promise for trauma surgery, where every minute matters, and for patients on blood thinners, whose bodies struggle to form protective clots naturally.
But significant work remains. The technology has only been tested in rats. Researchers need to see how these engineered clots perform in actual human patients, in real surgical and emergency settings. They also need to refine the formula for different scenarios—the current version isn't yet strong enough to seal high-pressure arterial bleeds, for instance. The team will need to fine-tune the gel's properties depending on whether it's being used to repair organ tissue or stop catastrophic bleeding.
Li and his colleagues are confident the approach has broad potential. If the human trials succeed, engineered blood clots could become a standard tool in operating rooms and trauma centers, a way to give the body's own healing machinery a crucial boost when seconds count. For now, the promise is real but still provisional—a laboratory breakthrough waiting to prove itself in the messier, more complex world of actual medicine.
Citations marquantes
Natural blood clots can be slow to form and mechanically fragile, which limits their ability to stop severe bleeding and can compromise healing.— Jianyu Li, mechanical engineer, McGill University
Engineered blood clots have strong potential for broad clinical use and could improve outcomes across many medical situations.— Jianyu Li
Envie de l'histoire complète ?
Lire l'original sur ScienceAlert ↗
Health & Medicine